IRON250117C100000
- 0.00
- 0.000.00%
Disc Medicine Newsroom
Disc Medicine Highlights 2025 Strategy and Financial Updates
Express News | Disc Medicine Inc: To Date, Co Has Not Identified Any Misstatements in Its Financial Statements
Express News | Disc Medicine : Material Weakness Is Related to Lack of Design and Maintenance of Effective Itgc Over Certain Key Financial It Systems
Express News | Disc Medicine:Expects to Report Material Weakness in Internal Control Over Financial Reporting in Annual Report on Form 10-K for Yt Ended Dec 31, 2024
An Intrinsic Calculation For Disc Medicine, Inc. (NASDAQ:IRON) Suggests It's 29% Undervalued
Disc Medicine Insider Sold Shares Worth $1,251,357, According to a Recent SEC Filing
Disc Medicine Is Maintained at Buy by Stifel
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $90
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $70 to $118
Express News | Disc Medicine Inc : Stifel Raises Target Price to $90 From $79
Disc Medicine (IRON) Gets a Buy From Wells Fargo
Promising Pipeline Developments Bolster Buy Rating for Disc Medicine
Disc Medicine Presents Data Showing Potential Benefits of 3 Investigational Drugs
Disc Medicine Highlights Clinical And Preclinical Data From BEACON And AURORA Trials Of Bitopertin And Phase 1 DISC-3405 Trial At ASH 2024, Showcasing Potential For Existing And New Indications While Advancing Pipeline Of Hematologic Disease Therapies
Scotiabank Remains a Buy on Disc Medicine (IRON)
Cantor Fitzgerald Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $99
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Disc Medicine (IRON) and BridgeBio Pharma (BBIO)
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $118
Douglas Tsao's Buy Rating for Disc Medicine: Promising Efficacy and Market Potential of DISC-0974 in Anemia Treatment
Promising Clinical Data and Strategic Advancements Drive Buy Rating for Disc Medicine